The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid.
CSF
LC-MS/MS
cenicriviroc
human serum albumin
plasma
Journal
Biomedical chromatography : BMC
ISSN: 1099-0801
Titre abrégé: Biomed Chromatogr
Pays: England
ID NLM: 8610241
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
12
04
2019
revised:
05
07
2019
accepted:
05
08
2019
pubmed:
20
10
2019
medline:
23
1
2020
entrez:
20
10
2019
Statut:
ppublish
Résumé
A high-performance liquid chromatography tandem mass spectrometric method was developed and validated for cenicriviroc (CVC) quantification in human plasma and cerebrospinal fluid (CSF). The method involved precipitation with acetonitrile and injecting supernatants onto the column. Separation was achieved on an XBridge C
Substances chimiques
Imidazoles
0
Sulfoxides
0
cenicriviroc
15C116UA4Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e4711Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
Alagaratnam, J., Dilly-Penchala, S., Challenger, E., Else, L., Legg, K., Petersen, C., … Winston, A. (2019). Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment. British Journal of Clinical Pharmacology, 85(5), 1039-1040. https://doi.org/10.1111/bcp.13878
Chen, C., Bajpai, L., Mollova, N., & Leung, K. (2009). Sensitive and cost-effective LC-MS/MS method for quantitation of CVT-6883 in human urine using sodium dodecylbenzenesulfonate additive to eliminate adsorptive losses. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 877(10), 943-947. https://doi.org/10.1016/j.jchromb.2009.02.045
Garvey, L., Nelson, M., Latch, N., Erlwein, O. W., Allsop, J. M., Mitchell, A., … Winston, A. (2012). CNS effects of a CCR5 inhibitor in HIV-infected subjects: A pharmacokinetic and cerebral metabolite study. The Journal of Antimicrobial Chemotherapy, 67(1), 206-212. https://doi.org/10.1093/jac/dkr427
Gu, H., Deng, Y., Wang, J., Aubry, A. F., & Arnold, M. E. (2010). Development and validation of sensitive and selective LC-MS/MS methods for the determination of BMS-708163, a gamma-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 878(25), 2319-2326. https://doi.org/10.1016/j.jchromb.2010.06.041
Ji, A. J., Jiang, Z., Livson, Y., Davis, J. A., Chu, J. X., & Weng, N. (2010). Challenges in urine bioanalytical assays: Overcoming nonspecific binding. Bioanalysis, 2(9), 1573-1586. https://doi.org/10.4155/bio.10.114
Kramer, V. G., Hassounah, S., Colby-Germinario, S. P., Oliveira, M., Lefebvre, E., Mesplede, T., & Wainberg, M. A. (2015). The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: Implications for plasma viral load and intracellular DNA decline. The Journal of Antimicrobial Chemotherapy, 70(3), 750-756. https://doi.org/10.1093/jac/dku451
Lalezari, J., Gathe, J., Brinson, C., Thompson, M., Cohen, C., Dejesus, E., … Palleja, S. M. (2011). Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. Journal of Acquired Immune Deficiency Syndromes, 57(2), 118-125. https://doi.org/10.1097/QAI.0b013e318213c2c0
Lefebvre, E., Gottwald, M., Lasseter, K., Chang, W., Willett, M., Smith, P. F., … Utay, N. S. (2016). Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment. Clinical and Translational Science, 9(3), 139-148. https://doi.org/10.1111/cts.12397
Marier, J. F., Trinh, M., Pheng, L. H., Palleja, S. M., & Martin, D. E. (2011). Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naive patients. Antimicrobial Agents and Chemotherapy, 55(6), 2768-2774. https://doi.org/10.1128/AAC.00713-10
Matuszewski, B. K., Constanzer, M. L., & Chavez-Eng, C. M. (2003). Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry, 75(13), 3019-3030.
Nouri, P. (2016). Challenges in CSF sample collection: Non-specific binding and bioanalysis of AD Biomarkers. Alzheimer's & Dementia, 12(7), P1140-P1141.
Palleja, S., Wang-Smith, L., Ogden, R., Martin, D., Driz, R., & Sapirstein, J. (2009). TBR-652, a chemokine receptor 5 (CCR5) antagonist, demonstrates good oral bioavailability and desirable pharmacokinetic (PK) and safety profiles in healthy volunteers. In 49th ICAAC, San Francisco, CA.
Silvester, S., & Zang, F. (2012). Overcoming non-specific adsorption issues for AZD9164 in human urine samples: Consideration of bioanalytical and metabolite identification procedures. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 893-894, 134-143. https://doi.org/10.1016/j.jchromb.2012.03.004
Tacke, F. (2018). Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opinion on Investigational Drugs, 27(3), 301-311. https://doi.org/10.1080/13543784.2018.1442436
US Food and Drug Administration (2018). Guidance for Industry: Bioanalytical method validation. Rockville, MD: US Food and Drug Administration.
Xu, Y., Du, L., Rose, M. J., Fu, I., Woolf, E. J., & Musson, D. G. (2005). Concerns in the development of an assay for determination of a highly conjugated adsorption-prone compound in human urine. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 818(2), 241-248. https://doi.org/10.1016/j.jchromb.2005.01.004